Back to top
more

Clearside Biomedical (CLSD)

(Delayed Data from NSDQ)

$1.34 USD

1.34
154,107

+0.08 (6.35%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $1.31 -0.03 (-2.24%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for CLSD

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Clearside Biomedical, Inc. [CLSD]

Reports for Purchase

Showing records 261 - 273 ( 273 total )

Company: Clearside Biomedical, Inc.

Industry: Unclassified

Record: 261

11/07/2016

Daily Note

Pages: 44

November and Full Year 2016 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 100.00

Research Provided by a Third Party

Company: Clearside Biomedical, Inc.

Industry: Unclassified

Record: 262

11/04/2016

Industry Report

Pages: 6

The Week Ahead in Life Sciences - Upcoming Events for the Week of Nov 7

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Clearside Biomedical, Inc.

Industry: Unclassified

Record: 263

10/25/2016

Company Report

Pages: 14

Advisory Call: SCS-Microinjection Advantages vs. IVT Drug Delivery for ME-RVO and Gene Therapy for the Eye; Reiterate OUTPERFORM and $28 Price Target

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 50.00

Research Provided by a Third Party

Company: Clearside Biomedical, Inc.

Industry: Unclassified

Record: 264

10/19/2016

Company Report

Pages: 10

AAO: Phase 2 Details for Zuprata Treatment of ME-RVO Reinforce Top Line Results In Our View; Reiterate OUTPERFORM and $28 Price Target

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Clearside Biomedical, Inc.

Industry: Unclassified

Record: 265

10/04/2016

Daily Note

Pages: 45

October and Full Year 2016 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 100.00

Research Provided by a Third Party

Company: Clearside Biomedical, Inc.

Industry: Unclassified

Record: 266

09/01/2016

Daily Note

Pages: 44

September and Full Year 2016 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 100.00

Research Provided by a Third Party

Company: Clearside Biomedical, Inc.

Industry: Unclassified

Record: 267

08/23/2016

Company Report

Pages: 25

Ophthalmology Expert Call: Next Generation Drug Delivery into Suprachoroidal Space Highlights Best-In-Class Profile; Reiterate OUTPERFORM and $28 PT.

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 75.00

Research Provided by a Third Party

Company: Clearside Biomedical, Inc.

Industry: Unclassified

Record: 268

08/15/2016

Daily Note

Pages: 15

Differentiated Zuprata ME-NIU -Clinical Results Presented in High Profile Session at ASRS; Reiterate OUTPERFORM and $28 Price Target

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 50.00

Research Provided by a Third Party

Company: Clearside Biomedical, Inc.

Industry: Unclassified

Record: 269

08/11/2016

Company Report

Pages: 6

Q2 Financials Update; Sufficiently Capitalized Through Pivotal Data in 2017; Reiterate OUTPERFORM and $28 PT

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Clearside Biomedical, Inc.

Industry: Unclassified

Record: 270

08/01/2016

Daily Note

Pages: 46

August and Full Year 2016 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 100.00

Research Provided by a Third Party

Company: Clearside Biomedical, Inc.

Industry: Unclassified

Record: 271

07/26/2016

Daily Note

Pages: 11

Additional Top Line Phase 2 Results Strengthen Zuprata(TM)''s Clinical Profile for ME-RVO, In Our View; Reiterate OUTPERFORM and $28 Price Target

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Clearside Biomedical, Inc.

Industry: Unclassified

Record: 272

07/01/2016

Industry Report

Pages: 46

July and Full Year 2016 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 100.00

Research Provided by a Third Party

Company: Clearside Biomedical, Inc.

Industry: Unclassified

Record: 273

06/24/2016

Company Report

Pages: 33

Initiating with an OUTPERFORM and $28 PT

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 75.00

Research Provided by a Third Party